# NSAIDs, Ileal Inflammation, and Glucose Metabolism: Insights from a Large Retrospective Cohort

**Authors:** Stephanie Hosanna Rodriguez, Gilles Jadd Hoilat, Nikash Pradhan, Carolina Gonzalez Bravo, Marcelo L. G. Correia, Mohamad Mokadem

PMC · DOI: 10.3390/nu17091514 · Nutrients · 2025-04-29

## TL;DR

This study found that NSAID use is not linked to ileitis or glucose metabolism issues, while IBD and traditional risk factors like age and BMI are more important.

## Contribution

The study provides new evidence that NSAID use does not significantly contribute to ileitis or glucose metabolism abnormalities.

## Key findings

- NSAID use was not significantly associated with biopsy-confirmed ileitis after adjustment.
- IBD was the strongest independent predictor of ileitis.
- Age and BMI were dominant predictors of glycemic abnormalities over ileitis.

## Abstract

Background/Objectives: Ileitis, or inflammation of the terminal ileum, is often linked to inflammatory bowel disease (IBD), especially Crohn’s disease, but may also arise from non-steroidal anti-inflammatory drug (NSAID) use. While NSAIDs are known to cause gastrointestinal injury, their role in ileitis and downstream metabolic consequences remains unclear. This study evaluated the relationship between NSAID use, biopsy-confirmed ileitis, and glucose metabolism abnormalities in patients with and without IBD. Methods: We conducted a retrospective cohort study of 3725 adults who underwent ileal biopsy between 2009 and 2022 at a tertiary care center. Patients were stratified based on histologic evidence of ileitis. Collected data included demographics, IBD status, NSAID and steroid use, hemoglobin A1C, fasting glucose, and diagnoses of abnormal glucose metabolism. Multivariable logistic and linear regression models adjusted for age, BMI, sex, steroid use, and IBD. Results: Of 3725 patients, 876 had biopsy-confirmed ileitis. NSAID use—categorized as current, historical, or inpatient—was not significantly associated with ileitis after adjustment. In contrast, IBD was the strongest independent predictor (p < 0.05). Although unadjusted analyses showed lower A1C in the ileitis group (p = 0.003), this was not significant after controlling for confounders (p = 0.084). No significant associations were found between ileitis and fasting glucose or abnormal glucose metabolism. Age and BMI were the dominant predictors of glycemic abnormalities. Conclusions: NSAID use was not associated with biopsy-confirmed ileitis or impaired glucose metabolism. Traditional metabolic risk factors were stronger predictors of glycemic abnormalities than localized ileal inflammation.

## Linked entities

- **Diseases:** inflammatory bowel disease (MONDO:0005265), Crohn’s disease (MONDO:0005011)

## Full-text entities

- **Diseases:** IBD (MESH:D015212), gastrointestinal injury (MESH:D005767), Crohn's disease (MESH:D003424), abnormal glucose metabolism (MESH:D044882), Ileitis (MESH:D007079), inflammation (MESH:D007249), Ileal Inflammation (MESH:D007077), glycemic abnormalities (MESH:D000014)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A1C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12073212/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12073212/full.md

---
Source: https://tomesphere.com/paper/PMC12073212